Erythropoietin (EPO) Drugs Market by Drug Class, Product Type, and Application- Global Industry Analysis & Forecast to 2027
Published On : September 2019 Pages : 154 Category: Pharma & Healthcare Report Code : HC095933
Erythropoietin (EPO) Drugs Market by Drug Class (Biologics, Biosimilars) Product Type (Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta, Others) Application (Cancer, Neurology, Hematology, Renal diseases) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The erythropoietin (EPO) drugs market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Erythropoietin (EPO) is created by the kidney and used to make red platelets. Red platelets are created in the bone marrow (the elastic tissue inside the bone). So as to make red platelets, the body keeps up a satisfactory stockpile of erythropoietin (EPO), a hormone that is created by the kidney.This erythropoietin (EPO) drugs are utilized for treatment of chemotherapy-induced anemia, anemia is a typical symptom happening because of chemotherapy of End Stage Renal Diseases (ESRD), HIV and cancer.
Drivers and Restraints
Growing prevalence of anemic condition drives the growth of erythropoietin (EPO) drugs market. Growing commercialization of erythropoietin biosimilars propels the growth of erythropoietin (EPO) drugs market. Increase in the incidences of chronic kidney disease fuels the growth of erythropoietin (EPO) drugs market. High cost of erythropoietin (EPO) drugs may hamper the growth erythropoietin (EPO) drugs market. Favorable reimbursement policies contribute to the growth of erythropoietin (EPO) drugs market. Fast approvals of EPO drugs provides beneficial opportunities for erythropoietin (EPO) drugs market.
Regional Insights
Among the geographies, North America is expected to dominate erythropoietin (EPO) drugs market. Growing prevalence of anemic condition in the region contribute to the growth of erythropoietin (EPO) drugs market.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Johnson & Johnson
- Dr. Reddy's Laboratories Ltd.
- LG Life Sciences Ltd.
- Celltrion, Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Biocon Limited
- Amgen Inc.
- Intas Pharmaceuticals Ltd.
- Hoffman-La Roche Ltd.
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
o Erythropoietin (EPO) Drugs Market, By Drug Class, Estimates and Forecast, 2017-2027 ($Million)
o Biologics
o Biosimilars
o Erythropoietin (EPO) Drugs Market, By Product Type, Estimates and Forecast, 2017-2027 ($Million)
o Epoetin-alfa
o Darbepoetin-alfa
o Epoetin-beta
o Others
o Erythropoietin (EPO) Drugs Market, By Application, Estimates and Forecast, 2017-2027 ($Million)
o Cancer
o Neurology
o Hematology
o Renal Diseases
o Erythropoietin (EPO) Drugs Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Johnson & Johnson
o Dr. Reddy's Laboratories Ltd.
o LG Life Sciences Ltd.
o Celltrion, Inc.
o Sun Pharmaceutical Industries Ltd.
o Teva Pharmaceutical Industries Ltd.
o Biocon Limited
o Amgen Inc.
o Intas Pharmaceuticals Ltd.
o Hoffman-La Roche Ltd.
o Erythropoietin (EPO) Drugs Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Erythropoietin (EPO) Drugs Market, By Country
o U.S. Erythropoietin (EPO) Drugs Market
o Canada Erythropoietin (EPO) Drugs Market
o Mexico Erythropoietin (EPO) Drugs Market
o Europe
§ Europe Erythropoietin (EPO) Drugs Market, By Country
o Germany Erythropoietin (EPO) Drugs Market
o UK Erythropoietin (EPO) Drugs Market
o France Erythropoietin (EPO) Drugs Market
o Russia Erythropoietin (EPO) Drugs Market
o Italy Erythropoietin (EPO) Drugs Market
o Rest of Europe Erythropoietin (EPO) Drugs Market
o Asia-Pacific
§ Asia-Pacific Erythropoietin (EPO) Drugs Market, By Country
o China Erythropoietin (EPO) Drugs Market
o Japan Erythropoietin (EPO) Drugs Market
o South Korea Erythropoietin (EPO) Drugs Market
o India Erythropoietin (EPO) Drugs Market
o Southeast Asia Erythropoietin (EPO) Drugs Market
o Rest of Asia-Pacific Erythropoietin (EPO) Drugs Market
o South America
§ South America Erythropoietin (EPO) Drugs Market, By Country
o Brazil Erythropoietin (EPO) Drugs Market
o Argentina Erythropoietin (EPO) Drugs Market
o Columbia Erythropoietin (EPO) Drugs Market
o Rest of South America Erythropoietin (EPO) Drugs Market
o Middle East and Africa
§ Middle East and Africa Erythropoietin (EPO) Drugs Market, By Country
o Saudi Arabia Erythropoietin (EPO) Drugs Market
o UAE Erythropoietin (EPO) Drugs Market
o Egypt Erythropoietin (EPO) Drugs Market
o Nigeria Erythropoietin (EPO) Drugs Market
o South Africa Erythropoietin (EPO) Drugs Market
o Rest of MEA Erythropoietin (EPO) Drugs Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Erythropoietin (EPO) Drugs Market, By Drug Class
5.1. Introduction
5.2. Global Erythropoietin (EPO) Drugs Revenue and Market Share by Drug Class (2017-2027)
5.2.1. Global Erythropoietin (EPO) Drugs Revenue and Revenue Share by Drug Class (2017-2027)
5.3. Biologics
5.3.1. Global Biologics Revenue and Growth Rate (2017-2027)
5.4. Biosimilars
5.4.1. Global Biosimilars Revenue and Growth Rate (2017-2027)
6. Erythropoietin (EPO) Drugs Market, By Product Type
6.1. Introduction
6.2. Global Erythropoietin (EPO) Drugs Revenue and Market Share by Product Type (2017-2027)
6.2.1. Global Erythropoietin (EPO) Drugs Revenue and Revenue Share by Product Type (2017-2027)
6.3. Epoetin-alfa
6.3.1. Global Epoetin-alfa Revenue and Growth Rate (2017-2027)
6.4. Darbepoetin-alfa
6.4.1. Global Darbepoetin-alfa Revenue and Growth Rate (2017-2027)
6.5. Epoetin-beta
6.5.1. Global Epoetin-beta Revenue and Growth Rate (2017-2027)
6.6. Others
6.6.1. Global Others Revenue and Growth Rate (2017-2027)
7. Erythropoietin (EPO) Drugs Market, By Application
7.1. Introduction
7.2. Global Erythropoietin (EPO) Drugs Revenue and Market Share by Application (2017-2027)
7.2.1. Global Erythropoietin (EPO) Drugs Revenue and Revenue Share by Application (2017-2027)
7.3. Cancer
7.3.1. Global Cancer Revenue and Growth Rate (2017-2027)
7.4. Neurology
7.4.1. Global Neurology Revenue and Growth Rate (2017-2027)
7.5. Hematology
7.5.1. Global Hematology Revenue and Growth Rate (2017-2027)
7.6. Renal Diseases
7.6.1. Global Renal Diseases Revenue and Growth Rate (2017-2027)
8. Erythropoietin (EPO) Drugs Market, By Region
8.1. Introduction
8.2. Global Erythropoietin (EPO) Drugs Revenue and Market Share by Regions
8.2.1. Global Erythropoietin (EPO) Drugs Revenue by Regions (2017-2027)
8.3. North America Erythropoietin (EPO) Drugs by Countries
8.3.1. North America Erythropoietin (EPO) Drugs Revenue and Growth Rate (2017-2027)
8.3.2. North America Erythropoietin (EPO) Drugs Revenue (Million USD) by Countries (2017-2027)
8.3.3. United States
8.3.3.1. United States Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.4. Canada
8.3.4.1. Canada Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.5. Mexico
8.3.5.1. Mexico Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.4. Europe Erythropoietin (EPO) Drugs by Countries
8.4.1. Europe Erythropoietin (EPO) Drugs Revenue and Growth Rate (2017-2027)
8.4.2. Europe Erythropoietin (EPO) Drugs Revenue (Million USD) by Countries (2017-2027)
8.4.3. Germany
8.4.3.1. Germany Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.4. France
8.4.4.1. France Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.5. UK
8.4.5.1. UK Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.6. Russia
8.4.6.1. Russia Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.7. Italy
8.4.7.1. Italy Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.8. Rest of Europe
8.4.8.1. Rest of Europe Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.5. Asia-Pacific Erythropoietin (EPO) Drugs by Countries
8.5.1. Asia-Pacific Erythropoietin (EPO) Drugs Revenue and Growth Rate (2017-2027)
8.5.2. Asia-Pacific Erythropoietin (EPO) Drugs Revenue (Million USD) by Countries (2017-2027)
8.5.3. China
8.5.3.1. China Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.4. Japan
8.5.4.1. Japan Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.5. Korea
8.5.5.1. Korea Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.6. India
8.5.6.1. India Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.7. Southeast Asia
8.5.7.1. Southeast Asia Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.8. Rest of Asia-Pacific
8.5.8.1. Rest of Asia-Pacific Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.6. South America Erythropoietin (EPO) Drugs by Countries
8.6.1. South America Erythropoietin (EPO) Drugs Revenue and Growth Rate (2017-2027)
8.6.2. South America Erythropoietin (EPO) Drugs Revenue (Million USD) by Countries (2017-2027)
8.6.3. Brazil
8.6.3.1. Brazil Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.4. Argentina
8.6.4.1. Argentina Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.5. Columbia
8.6.5.1. Columbia Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.6. Rest of South America
8.6.6.1. Rest of South America Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7. Middle East and Africa Erythropoietin (EPO) Drugs by Countries
8.7.1. Middle East and Africa Erythropoietin (EPO) Drugs Revenue and Growth Rate (2017-2027)
8.7.2. Middle East and Africa Erythropoietin (EPO) Drugs Revenue (Million USD) by Countries (2017-2027)
8.7.3. Saudi Arabia
8.7.3.1. Saudi Arabia Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.4. United Arab Emirates
8.7.4.1. United Arab Emirates Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.5. Egypt
8.7.5.1. Egypt Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.6. Nigeria
8.7.6.1. Nigeria Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.7. South Africa
8.7.7.1. South Africa Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.8. Turkey
8.7.8.1. Turkey Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.9. Rest of Middle East and Africa
8.7.9.1. Rest of Middle East and Africa Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
9. Company Profiles
9.1. Johnson & Johnson
9.1.1. Business Overview
9.1.2. Service Portfolio
9.1.3. Strategic Developments
9.1.4. Financial Overview
9.2. Dr. Reddy's Laboratories Ltd.
9.2.1. Business Overview
9.2.2. Service Portfolio
9.2.3. Strategic Developments
9.2.4. Financial Overview
9.3. LG Life Sciences Ltd.
9.3.1. Business Overview
9.3.2. Service Portfolio
9.3.3. Strategic Developments
9.3.4. Financial Overview
9.4. Celltrion, Inc.
9.4.1. Business Overview
9.4.2. Service Portfolio
9.4.3. Strategic Developments
9.4.4. Financial Overview
9.5. Sun Pharmaceutical Industries Ltd.
9.5.1. Business Overview
9.5.2. Service Portfolio
9.5.3. Strategic Developments
9.5.4. Financial Overview
9.6. Teva Pharmaceutical Industries Ltd.
9.6.1. Business Overview
9.6.2. Service Portfolio
9.6.3. Strategic Developments
9.6.4. Financial Overview
9.7. Biocon Limited
9.7.1. Business Overview
9.7.2. Service Portfolio
9.7.3. Strategic Developments
9.7.4. Financial Overview
9.8. Amgen Inc.
9.8.1. Business Overview
9.8.2. Service Portfolio
9.8.3. Strategic Developments
9.8.4. Financial Overview
9.9. Intas Pharmaceuticals Ltd.
9.9.1. Business Overview
9.9.2. Service Portfolio
9.9.3. Strategic Developments
9.9.4. Financial Overview
9.10. Hoffman-La Roche Ltd.
9.10.1. Business Overview
9.10.2. Service Portfolio
9.10.3. Strategic Developments
9.10.4. Financial Overview
10. Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.1. Global Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
10.2. Erythropoietin (EPO) Drugs Market Forecast by Regions (2017-2027)
10.2.1. North America Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.1.1. United States Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.1.2. Canada Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.1.3. Mexico Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.2. Europe Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.2.1. Germany Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.2.2. France Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.2.3. UK Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.2.4. Russia Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.2.5. Italy Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.2.6. Rest of Europe Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.3. Asia-Pacific Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.3.1. China Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.3.2. Japan Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.3.3. Korea Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.3.4. India Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.3.5. Southeast Asia Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.3.6. Rest of Asia-Pacific Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.4. South America Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.4.1. Brazil Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.4.2. Argentina Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.4.3. Columbia Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.4.4. Rest of South America Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.5. Middle East and Africa Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.5.1. Saudi Arabia Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.5.2. United Arab Emirates Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.5.3. Egypt Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.5.4. Nigeria Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.5.5. South Africa Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.5.6. Turkey Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.2.5.7. Rest of Middle East and Africa Erythropoietin (EPO) Drugs Market Forecast (2017-2027)
10.3. Erythropoietin (EPO) Drugs Market Forecast by Drug Class (2017-2027)
10.3.1. Erythropoietin (EPO) Drugs Forecast by Drug Class (2017-2027)
10.3.2. Erythropoietin (EPO) Drugs Market Share Forecast by Drug Class (2017-2027)
10.4. Erythropoietin (EPO) Drugs Market Forecast by Product Type (2017-2027)
10.4.1. Erythropoietin (EPO) Drugs Forecast by Product Type (2017-2027)
10.4.2. Erythropoietin (EPO) Drugs Market Share Forecast by Product Type (2017-2027)
10.5. Erythropoietin (EPO) Drugs Market Forecast by Application (2017-2027)
10.5.1. Erythropoietin (EPO) Drugs Forecast by Application (2017-2027)
10.5.2. Erythropoietin (EPO) Drugs Market Share Forecast by Application (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Erythropoietin (EPO) Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Erythropoietin (EPO) Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Erythropoietin (EPO) Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Erythropoietin (EPO) Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Erythropoietin (EPO) Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Erythropoietin (EPO) Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Erythropoietin (EPO) Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Erythropoietin (EPO) Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Erythropoietin (EPO) Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Erythropoietin (EPO) Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Erythropoietin (EPO) Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Erythropoietin (EPO) Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Erythropoietin (EPO) Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Erythropoietin (EPO) Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Erythropoietin (EPO) Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Erythropoietin (EPO) Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Erythropoietin (EPO) Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Erythropoietin (EPO) Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Erythropoietin (EPO) Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Erythropoietin (EPO) Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Erythropoietin (EPO) Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Erythropoietin (EPO) Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Erythropoietin (EPO) Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Erythropoietin (EPO) Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Erythropoietin (EPO) Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Erythropoietin (EPO) Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Erythropoietin (EPO) Drugs Revenue and Revenue Share by Drug Class (2017-2018)
Figure Global Biologics Revenue and Growth Rate (2017-2018)
Figure Global Biosimilars Revenue and Growth Rate (2017-2018)
Table Global Erythropoietin (EPO) Drugs Revenue and Revenue Share by Product Type (2017-2018)
Figure Global Epoetin-alfa Revenue and Growth Rate (2017-2018)
Figure Global Darbepoetin-alfa Revenue and Growth Rate (2017-2018)
Figure Global Epoetin-beta Revenue and Growth Rate (2017-2018)
Figure Global Others Revenue and Growth Rate (2017-2018)
Table Global Erythropoietin (EPO) Drugs Revenue and Revenue Share by Application (2017-2018)
Figure Global Cancer Revenue and Growth Rate (2017-2018)
Figure Global Neurology Revenue and Growth Rate (2017-2018)
Figure Global Hematology Revenue and Growth Rate (2017-2018)
Figure Global Renal Diseases Revenue and Growth Rate (2017-2018)
Table Global Erythropoietin (EPO) Drugs Revenue by Regions (2017-2018)
Figure North America Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure North America Erythropoietin (EPO) Drugs Revenue and Growth Rate (2017-2018)
Figure North America Erythropoietin (EPO) Drugs by Countries (2017-2018)
Figure North America Erythropoietin (EPO) Drugs Revenue (Million USD) by Countries (2017-2018)
Figure United States Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure United States Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure Canada Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure Mexico Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure Europe Erythropoietin (EPO) Drugs Revenue and Growth Rate (2017-2018)
Figure Europe Erythropoietin (EPO) Drugs by Countries (2017-2018)
Figure Europe Erythropoietin (EPO) Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Germany Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure Germany Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure France Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure UK Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure Russia Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure Italy Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure Rest of Europe Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure Asia-Pacific Erythropoietin (EPO) Drugs Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Erythropoietin (EPO) Drugs by Countries (2017-2018)
Figure Asia-Pacific Erythropoietin (EPO) Drugs Revenue (Million USD) by Countries (2017-2018)
Figure China Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure China Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure Japan Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure Korea Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure India Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure Southeast Asia Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure South America Erythropoietin (EPO) Drugs Revenue and Growth Rate (2017-2018)
Figure South America Erythropoietin (EPO) Drugs by Countries (2017-2018)
Figure South America Erythropoietin (EPO) Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure Brazil Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure Argentina Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure Columbia Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure Rest of South America Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure Middle East and Africa Erythropoietin (EPO) Drugs Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Erythropoietin (EPO) Drugs by Countries (2017-2018)
Figure Middle East and Africa Erythropoietin (EPO) Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure Saudi Arabia Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure United Arab Emirates Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure Egypt Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure Nigeria Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure South Africa Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure Turkey Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Erythropoietin (EPO) Drugs Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Table Johnson & Johnson Erythropoietin (EPO) Drugs Financial Overview
Table Dr. Reddy's Laboratories Ltd. Erythropoietin (EPO) Drugs Financial Overview
Table LG Life Sciences Ltd. Erythropoietin (EPO) Drugs Financial Overview
Table Celltrion, Inc. Erythropoietin (EPO) Drugs Financial Overview
Table Sun Pharmaceutical Industries Ltd. Erythropoietin (EPO) Drugs Financial Overview
Table Teva Pharmaceutical Industries Ltd. Erythropoietin (EPO) Drugs Financial Overview
Table Biocon Limited Erythropoietin (EPO) Drugs Financial Overview
Table Amgen Inc. Erythropoietin (EPO) Drugs Financial Overview
Table Intas Pharmaceuticals Ltd. Erythropoietin (EPO) Drugs Financial Overview
Table Hoffman-La Roche Ltd. Erythropoietin (EPO) Drugs Financial Overview
Figure Global Erythropoietin (EPO) Drugs Revenue (Millions USD) and Growth Rate (2018-2025)
Table Erythropoietin (EPO) Drugs Market Forecast by Regions (2018-2025)
Figure North America Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure United States Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure Canada Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure Mexico Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure Europe Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure Germany Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure France Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure UK Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure Russia Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure Italy Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure Rest of Europe Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure Asia-Pacific Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure China Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure Japan Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure Korea Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure India Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure Southeast Asia Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure South America Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure Brazil Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure Argentina Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure Columbia Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure Rest of South America Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure Middle East and Africa Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure Saudi Arabia Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure United Arab Emirates Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure Egypt Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure Nigeria Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure South Africa Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure Turkey Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Erythropoietin (EPO) Drugs Market Forecast (2018-2025)
Figure Global Erythropoietin (EPO) Drugs Forecast by Drug Class (2018-2025)
Figure Global Erythropoietin (EPO) Drugs Market Share Forecast by Drug Class (2018-2025)
Figure Global Erythropoietin (EPO) Drugs Forecast by Drug Class (2018-2025)
Figure Global Erythropoietin (EPO) Drugs Forecast by Product Type (2018-2025)
Figure Global Erythropoietin (EPO) Drugs Market Share Forecast by Product Type (2018-2025)
Figure Global Erythropoietin (EPO) Drugs Forecast by Product Type (2018-2025)
Figure Global Erythropoietin (EPO) Drugs Forecast by Application (2018-2025)
Figure Global Erythropoietin (EPO) Drugs Market Share Forecast by Application (2018-2025)
Figure Global Erythropoietin (EPO) Drugs Forecast by Application (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|